Unknown

Dataset Information

0

Recent research trends and updates on nonalcoholic fatty liver disease.


ABSTRACT: Nonalcoholic fatty liver disease (NAFLD), together with metabolic syndrome and obesity, has shown a rapid increase in prevalence worldwide and is emerging as a major cause of chronic liver disease and liver transplantation. Among the various phenotypes of NAFLD, nonalcoholic steatohepatitis (NASH) is highly likely to progress to development of end-stage liver disease and cardiometabolic disease, resulting in liver-related and non-liver-related mortality. Nonetheless, there is no standardized pharmacotherapy against NASH and many drugs are under development in ongoing clinical trials. To develop a successful anti-NASH drug, it is necessary to select an appropriate target population and treatment outcomes depending on whether the mode of action is anti-metabolic, anti-inflammatory or anti-fibrotic. Recently, innovative surrogate markers have been investigated to replace hard outcomes such as liver histology and mortality and reduce the clinical trial duration. Currently, several drugs with fast track designation are being tested in phase III clinical trials, and many other drugs have moved into phase II clinical trials. Both lean NAFLD and typical obese NAFLD have been extensively studied and genetic variants such as PNPLA3 and TM6SF2 have been identified as significant risk factors for lean NAFLD. In the near future, noninvasive biomarkers and effective targeted therapies for NASH and associated fibrosis are required to develop precision medicine and tailored therapy according to various phenotypes of NAFLD.

SUBMITTER: Yoo JJ 

PROVIDER: S-EPMC6435971 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Recent research trends and updates on nonalcoholic fatty liver disease.

Yoo Jeong-Ju JJ   Kim Won W   Kim Moon Young MY   Jun Dae Won DW   Kim Sang Gyune SG   Yeon Jong-Eun JE   Lee Jin Woo JW   Cho Yong Kyun YK   Park Sang Hoon SH   Sohn Joo Hyun JH  

Clinical and molecular hepatology 20180808 1


Nonalcoholic fatty liver disease (NAFLD), together with metabolic syndrome and obesity, has shown a rapid increase in prevalence worldwide and is emerging as a major cause of chronic liver disease and liver transplantation. Among the various phenotypes of NAFLD, nonalcoholic steatohepatitis (NASH) is highly likely to progress to development of end-stage liver disease and cardiometabolic disease, resulting in liver-related and non-liver-related mortality. Nonetheless, there is no standardized pha  ...[more]

Similar Datasets

| S-EPMC7238455 | biostudies-literature
| S-EPMC4491606 | biostudies-literature
2011-01-05 | E-GEOD-26225 | biostudies-arrayexpress
| S-EPMC8237139 | biostudies-literature
| S-EPMC7460697 | biostudies-literature
| S-EPMC4482455 | biostudies-literature
| S-EPMC3278533 | biostudies-literature
| S-EPMC5643282 | biostudies-literature
| S-EPMC5401764 | biostudies-literature
| S-EPMC5380579 | biostudies-literature